People who received COVID-19 vaccine outside the United States

There are three scenarios outlined below.

1. People who were vaccinated outside the United States with a currently FDA-approved or FDA-authorized COVID-19 vaccine who:
   • Received all of the recommended doses of a single dose or 2-dose primary COVID-19 vaccine series are considered fully vaccinated 2 weeks after completion of the series. People who are moderately or severely immunocompromised and were vaccinated with a 2-dose mRNA COVID-19 vaccine primary series should receive an additional primary dose as detailed in Considerations for COVID-19 vaccination in moderately or severely immunocompromised people. People vaccinated with an FDA-approved or FDA-authorized COVID-19 vaccine outside the United States should also follow guidance for booster doses as detailed in the Booster dose.
   • Received the first dose of a 2-dose mRNA COVID-19 vaccine series do not need to restart the vaccine series in the United States. They should complete the series with an mRNA vaccine as close to the recommended time as possible and are considered fully vaccinated upon completion of the 2-dose primary series. People who were vaccinated in countries where only a single mRNA dose is recommended in certain populations (e.g., persons with a history of SARS-CoV-2 infection, adolescents) are not considered fully vaccinated in the United States until after completion of the 2-dose series.
2. People who completed all of the recommended doses of a COVID-19 vaccine listed for emergency use by WHO but not approved or authorized by FDA, or people who completed a heterologous (mix and match) series composed of doses of a COVID-19 vaccine listed for emergency use by WHO, at least one of which is a non-FDA-approved or authorized vaccine, are considered fully vaccinated 2 weeks after completion of the series.
   • Under the EUI, moderately or severely immunocompromised people ≥12 years of age should receive an additional primary dose of Pfizer-BioNTech COVID-19 Vaccine (30 µg formulation at least 28 days after receiving the second vaccine dose of their primary series as detailed in Considerations for COVID-19 vaccination in moderately or severely immunocompromised people.
   • Under the EUI, people ≥18 years of age (including moderately or severely immunocompromised people who received an additional primary dose) should receive a single booster dose of Pfizer-BioNTech COVID-19 Vaccine (30 µg formulation [purple or gray cap]) at least 6 months after completing their primary series, as detailed in the Booster dose Those who are 16 or 17 years old may get a booster dose.
3. People who received only the first dose of a multidose WHO-EUL COVID-19 primary series4 that is not FDA-approved or FDA-authorized, or who received all or some of the recommended doses of a COVID-19 vaccine primary series that is not listed for emergency use by WHO:
   • Should be offered primary vaccination with an FDA-approved or FDA-authorized COVID-19 vaccine (i.e., 2-dose mRNA series or single Janssen dose), with a minimum interval of at least 28 days since receipt of the last dose of a non-FDA-approved/authorized vaccine.
   • After completion of primary vaccination with an FDA-approved or FDA-authorized COVID-19 vaccine, these individuals are considered fully vaccinated, and are not recommended to receive an additional primary or booster dose at this time.